Steatotic liver disease (SLD), including metabolic dysfunction-associated steatohepatitis (MASH) and metabolic dysfunction-associated steatotic liver disease (MASLD), is one of the most common forms of chronic liver disease, with an estimated prevalence of about 30 percent across many countries.
The I148M genotype variant of the PNPLA3 gene is associated with MASH / MASLD disease severity and fibrosis progression even in the absence of classical metabolic dysfunction (including obesity). Conversely, single nucleotide polymorphisms (SNPs) within or close to the hydroxysteroid 17-β dehydrogenase 13 (HSD17B13) gene is associated with reduced risk and severity of MASH / MASLD disease and as such both genes are of significant research interest to the field.
The expert speakers will focus on how using PNPLA3 and HSD17B13 clinical trial assays for clinical trial use and a PNPLA3 genotyping kit for research use provide researchers with better insights into MASH/MASLD biology. This webinar explores some of the realities of a precision medicine approach to SLD from a diagnostic providers’ perspective.
Register for this webinar today to discuss the impact of genetic markers on the severity and treatment of MASH/MASLD and how clinical trial assays and genotyping kits can enhance research and clinical insight.
Speakers
Dr. Steven Walker, Director of Product Management, Almac Diagnostic Services
Dr. Steven Walker heads up the product management activities at Almac Diagnostic Services. Specifically, this includes the development of novel biomarker assays towards commercialisation to aid pharma and biotech companies in their drug development programmes.
Dr. Steven studied at the University of Dundee, leading to a PhD before postgraduate work at the Beatson Cancer Research UK Institute in Glasgow. He joined Almac Diagnostic Services in 2005, initially with the research team before taking the role in Product Development. As part of his time with the research team, he was involved in the discovery and development of several of the internally discovered biomarker assays at Almac and led the development of novel products such as the Almac claraT Total mRNA report.
Message Presenter
Dr. Cheryl McFarlane, Associate Director, Assay Development & Validation, Almac Diagnostic Services
Dr. Cheryl McFarlane has worked for over 15 years in the field of translational molecular oncology and holds the post of Associate Director of Assay Development & Validation at Almac Diagnostic Services where she has responsibility for assay development and validation activities supporting biomarker discovery, development and delivery for a range of Global Biopharma clients.
Prior to joining Almac in 2015, Dr McFarlane obtained a PhD from Queen’s University Belfast. She subsequently completed postdoctoral fellowships where she specialised in the identification and validation of novel therapeutic targets in the Ubiquitin Proteasome system.
Message PresenterWho Should Attend?
This webinar will appeal to pharma/biotech companies working on chronic disease indication focus, in particular steatotic liver disease including MASH/MASLD. In addition, the webinar will be interesting to liver disease researchers doing basic liver research and who may be interested in a precision medicine approach. This webinar will benefit decision-makers with responsibilities including, but not limited to:
- Biomarker programmes
- Project management/Clinical development
- CDx development
- Endocrinologists/Hepatologists/Gastroenterologists
What You Will Learn
Attendees will learn about:
- The importance of a precision medicine approach in Steatotic Liver Disease
- Developing liver genotyping assays that are highly accurate, sensitive & specific
- Almac PNPLA3 and HSD17B13 CTAs and Almac PNPLA3 Genotyping Kit Overview
- Assay utility and performance
Xtalks Partner
Almac Diagnostic Services
ALMAC GROUP:
The Almac Group is an established contract development and manufacturing organisation providing an extensive range of integrated services across the drug development lifecycle to the pharmaceutical and biotech sectors globally. Our innovative services range from R&D, biomarker discovery development and commercialisation, API manufacture, formulation development, clinical trial supply, IRT (IVRS/IWRS) through to commercial-scale manufacture.
The international company is a privately owned organisation that has grown organically over the past five decades now employing over 7,500 highly skilled personnel across 18 facilities including Europe, the US and Asia.
We have a global reputation for excellence built over 50 years of client service, delivering expertise right across the drug development lifecycle and offering a tailored solution to each of our clients. We will be exceptional, always.
Click here to find out more.
ALMAC DIAGNOSTIC SERVICES:
We are a precision medicine company specialising in biomarker-driven clinical trials. Our global CLIA and CAP accredited laboratories cover UK, Europe, USA and APAC regions.
Our cores services:
Genomic Services
We offer a range of genomics platform and chemistry options, alongside expert data sciences support & a specialty central lab service.
Clinical Biomarker & CDx Development
Custom Clinical Biomarker & CDx development, validation & delivery service from our CLIA & CAP accredited laboratories in USA, Europe and APAC.
Clinical Testing
Global clinical trial testing service from our clinical laboratories, including a menu of platforms & assays and an integrated specimen collection & logistics service.
Click here to find out more.
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account